Skip to main content

Table 2 Pathological response rate

From: Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

 

SOX arm

mFOLFOX6 arm

Total

 

n=53 (%)

n=48 (%)

n=101 (%)

Grade 0

6 (11.3)

5 (10.4)

11 (10.9)

Grade 1a

24 (45.3)

22 (45.8)

46 (45.6)

Grade 1b

12 (22.6)

8 (16.7)

20 (19.8)

Grade 2

8 (15.1)

12 (25.0)

20 (19.8)

Grade 3

2 (3.8)

1 (2.1)

3 (3.0)

Unknown

1 (1.9)

0 (0.0)

1 (1.0)

  1. SOX: S-1 and oxaliplatin, mFOLFOX6: folinic acid, 5-FU, and oxaliplatin
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us